Eli Lilly

News from Abroad: Lilly Successfully Defends Zyprexa Compound Patent In Australia

by McDonnell Boehnen Hulbert & Berghoff LLP on 3/28/2013

Originally published in Wrays on March 27, 2013. On 15 March 2013, the Australian Federal Court upheld Eli Lilly's patent for the active compound in their highly successful product ZYPREXA®. Lilly successfully...more

Court Report -- March 03, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 3/4/2013

In This Issue: Eli Lilly and Company et al. v. Genentech, Inc. et al.; Depomed Inc. v. Watson Laboratories Inc. - Florida et al.; Eli Lilly and Company v. Accord Healthcare Inc., USA; Endo Pharmaceuticals Inc. et al....more

Distributors Should Be Analyzed As Any Other Third Party Representative in the Sales Chain

by Thomas Fox on 2/25/2013

Ed. Note-David Simon is a partner at Foley and Lardner and Bill Athanas is a partner at Waller Lansden Dortch & Davis, LLP. Both have practices which include FCPA compliance. After my recent post on distributors under the...more

Distributors under the FCPA

by Thomas Fox on 2/13/2013

If there was ever a question that distributors were covered under the Foreign Corrupt Practices Act (FCPA), in 2012, the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) made it emphatically clear that...more

Failing To Act: Lessons From 2012 FCPA Enforcement

by Michael Volkov on 2/12/2013

FCPA practitioners tend to repeat themselves. Some of the points we make need to be repeated, and some do not. Businesses are not able to react as quickly as they should in response to potential risks and possible...more

Transaction Monitoring Under the FCPA [Video]

by Thomas Fox on 1/31/2013

Transaction monitoring was mentioned in a couple of significant enforcement actions of 2012. I think that it will move to becoming a best practice in FCPA compliance programs. This video will explain how transaction...more

Internal Audit Review of Charitable Donations Under the FCPA

by Thomas Fox on 1/10/2013

When is a rose not a rose? When it is a charitable donation not made for philanthropic purposes and it violates the Foreign Corrupt Practices Act (FCPA). I thought about that concept when reviewing the Eli Lilly and Company...more

Top Ten Enforcement Actions for 2012

by Thomas Fox on 1/8/2013

As we welcome in 2013, it is appropriate to reflect back on some of the things which have occurred over 2012 and in the Foreign Corrupt Practices Act (FCPA) enforcement world, it was quite a significant year. The Department...more

The Lilly FCPA Enforcement Action (Part III) Lessons Learned from Russia

by Thomas Fox on 1/4/2013

This Part III is the final installment of my review of the Eli Lilly and Company (Lilly) FCPA enforcement action brought by the Securities and Exchange Commission (SEC). In this Part III, I will review the FCPA issues that...more

The Eli Lilly FCPA Enforcement Action-Lessons Learned [Video]

by Thomas Fox on 1/3/2013

The Lilly FCPA enforcement action, as laid out in the SEC Complaint, provides the compliance practitioner with solid information which can be used in a variety of ways to strengthen an anti-corruption/anti-bribery compliance...more

From China to Poland and Brazi l- The Lilly FCPA Enforcement Action- Part II

by Thomas Fox on 1/3/2013

In Parts II and III of my review of the Eli Lilly and Company (Lilly) Foreign Corrupt Practices Act (FCPA) enforcement action brought by the Securities and Exchange Commission (SEC), I will discuss some the processes and...more

The Lilly FCPA Enforcement Action Part I – Key Lessons Learned on Sportsmanlike Conduct

by Thomas Fox on 12/31/2012

As you see from today’s picture I am enthusiastically wearing a New England Patriots (classic) shirt. You may ask yourself why am I wearing this shirt? The reason is because of a rather rash wager I made with Jay Rosen, Vice...more

Federal Circuit To Hear Oral Arguments In Myriad Remand Today

by Foley & Lardner LLP on 7/20/2012

Later today the Federal Circuit will hear oral arguments in Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case), which is on remand in view of the Supreme Court decision in Mayo...more

Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief

by Foley & Lardner LLP on 6/20/2012

Eli Lilly filed an interesting amicus brief in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case). The Lilly brief focuses on claim 20 of Myriad’s U.S. Patent...more

Seventh Circuit Jumps Ahead of SCOTUS, Rules Pharmaceutical Sales Reps Exempt from Overtime—Jackson Lewis’ Noel Tripp [Video]

by LXBN on 5/23/2012

Though the Seventh Circuit Court of Appeals’ Schaefer-Larose v. Eli Lilly & Co and Supreme Court’s recently-heard Christopher v. SmithKline Beecham Corp. aren’t the exact same, they come down deciding the same crucial issue:...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

News from Abroad: Lilly Successfully Defends Zyprexa Compound Patent In Australia

Court Report -- March 03, 2013

Distributors Should Be Analyzed As Any Other Third Party Representative in the Sales Chain

Distributors under the FCPA

Failing To Act: Lessons From 2012 FCPA Enforcement

Transaction Monitoring Under the FCPA [Video]

Internal Audit Review of Charitable Donations Under the FCPA

Top Ten Enforcement Actions for 2012

The Lilly FCPA Enforcement Action (Part III) Lessons Learned from Russia

The Eli Lilly FCPA Enforcement Action-Lessons Learned [Video]

From China to Poland and Brazi l- The Lilly FCPA Enforcement Action- Part II

The Lilly FCPA Enforcement Action Part I – Key Lessons Learned on Sportsmanlike Conduct

Federal Circuit To Hear Oral Arguments In Myriad Remand Today

Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief

Seventh Circuit Jumps Ahead of SCOTUS, Rules Pharmaceutical Sales Reps Exempt from Overtime—Jackson Lewis’ Noel Tripp [Video]

Transaction Monitoring Under the FCPA [Video]

The Eli Lilly FCPA Enforcement Action-Lessons Learned [Video]

Seventh Circuit Jumps Ahead of SCOTUS, Rules Pharmaceutical Sales Reps Exempt from Overtime—Jackson Lewis’ Noel Tripp [Video]

Expand Your Reach